La obesidad se ha convertido en un serio problema de salud pública. En este oportuno ensayo, Naief Yehya nos ofrece un ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Other drugs in development for CHB include Dicerna (now part of Novo Nordisk) and Roche’s siRNA candidate xalnesiran, which reported phase 2 data at the AASLD conference last year, and Arrowhead ...